Making AI Headlines · Page 4
OpenEvidence's Growth Comes With Questions
· New York time
OpenEvidence, an ad-supported medical AI startup valued at $15 billion, is growing rapidly while facing questions about accuracy and advertising, Ars Technica reports. Its business brings two demanding subjects into the same room: medical information and the commercial machinery that helps pay for its delivery. For physicians using an AI information service, usefulness depends on more than receiving a fluent answer quickly. Accuracy matters, and advertising raises a separate question about how commercial material appears alongside information intended to support professional work. A polished interface cannot settle either issue merely by looking reassuringly clinical. The reported questions do not establish that every answer is wrong or that every advertisement compromises a result. They identify areas requiring scrutiny as the service expands. Nor does a $15 billion valuation measure medical reliability. Investors and clinicians are assessing different things, even when both would appreciate a better outcome by the end of the quarter. The company's growth shows the appeal of faster access to medical information. Its business model also puts familiar internet economics inside a particularly consequential setting. Online advertising has long wanted to meet users at the moment of intent. Medicine adds the inconvenient requirement that the answer be useful for reasons beyond the advertiser's enthusiasm.
Read this story in the full newspaper →Satire. Not factual reporting. Read the original reporting from the linked publishers.